Heron Therapeutics Financials - Benzinga

Heron Therapeutics Inc

HRTXNASDAQ

Trade with Public

Trade with Public

$0.3060

近くで: Sep 30, 5:00 PM EST

$0.2901

-0.0159-5.2%

時間外: 7:22 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Heron Therapeutics Financials

Heron Therapeutics (HRTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share

Benzinga Newsdesk

PRO
Heron Therapeutics Affirms FY2026 Sales Guidance of $173.000M-$183.000M vs $174.733M Est

Benzinga Newsdesk

PRO
Heron Therapeutics Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $34.711M Miss $38.350M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

PRO
Heron Therapeutics Sees FY2026 Sales $173.000M-$183.000M vs $171.733M Est

Benzinga Newsdesk

Earnings Breakdown: Heron Therapeutics Q4

Benzinga Insights

© 2026 Benzinga | All Rights Reserved